{"nctId":"NCT05325853","briefTitle":"A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population","startDateStruct":{"date":"2022-04-06","type":"ACTUAL"},"conditions":["Anesthesia, Local"],"count":61,"armGroups":[{"label":"AG-920","type":"EXPERIMENTAL","interventionNames":["Drug: AG-920"]},{"label":"Proparacaine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Proparacaine Ophthalmic"]}],"interventions":[{"name":"AG-920","otherNames":["articaine"]},{"name":"Proparacaine Ophthalmic","otherNames":["Proparacaine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Pre-pubescent with no childbearing potential\n2. Capable of undergoing an eye exam\n3. Subject's legally appointed and authorized representative willing to sign and date an informed consent form (ICF) and, where appropriate, the subject willing to sign an assent form prior to any study-related procedures being performed.\n4. Parent/legal guardian and subject are willing and able to follow instructions and can be present for the required study visits and Follow-up Phone Call for the duration of the study.\n5. Have a healthy, normal cornea.\n\nExclusion Criteria:\n\n1. Have participated in an investigational study (drug or device) within the past 30 days.\n2. Have a known contraindication to local anesthetics.\n3. Children with known autism spectrum disorders or known to have heightened sensitivity.\n4. Corneal pathology that would make the corneal sensitivity lower/higher or make the test hard to perform or interpret.\n5. Have low visual acuity\n6. Manifest nystagmus\n7. Have had ocular surgery or general surgery within the past 45 days.\n8. Have had an intravitreal injection in either eye within 14 days of randomization.\n9. Have ocular surface disease.","healthyVolunteers":true,"sex":"ALL","maximumAge":"10 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Proportion of Participants in Which an Eye Exam Was Able to be Performed","description":"Was the investigator was able to perform the eye examination without additional anesthesia","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"TEAEs will be summarized by treatment group using frequency and percent for each system, organ, class (SOC) and preferred term within each SOC. Summaries will be presented separately for ocular and non-ocular Adverse Events (AEs).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":[]}}}